AZN Stock Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£100.32 |
| 52 Week High | UK£123.92 |
| 52 Week Low | UK£97.78 |
| Beta | 0.18 |
| 1 Month Change | -1.82% |
| 3 Month Change | -5.91% |
| 1 Year Change | -10.16% |
| 3 Year Change | 26.40% |
| 5 Year Change | 65.76% |
| Change since IPO | 1,410.84% |
Recent News & Updates
Shareholder Returns
| AZN | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.5% | -0.6% | -0.5% |
| 1Y | -10.2% | -6.6% | -5.3% |
Return vs Industry: AZN underperformed the UK Pharmaceuticals industry which returned -6.6% over the past year.
Return vs Market: AZN underperformed the UK Market which returned -5.3% over the past year.
Price Volatility
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 12.0% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AZN is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AZN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 83,500 | Pascal Soriot | https://www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19.
AstraZeneca PLC Fundamentals Summary
| AZN fundamental statistics | |
|---|---|
| Market Cap | UK£155.49b |
| Earnings (TTM) | UK£4.65b |
| Revenue (TTM) | UK£35.46b |
33.5x
P/E Ratio4.4x
P/S RatioIs AZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZN income statement (TTM) | |
|---|---|
| Revenue | US$44.99b |
| Cost of Revenue | US$4.87b |
| Gross Profit | US$40.12b |
| Other Expenses | US$34.23b |
| Earnings | US$5.90b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 08, 2024
| Earnings per share (EPS) | 3.80 |
| Gross Margin | 89.17% |
| Net Profit Margin | 13.10% |
| Debt/Equity Ratio | 76.8% |
How did AZN perform over the long term?
See historical performance and comparison